NYSE Euronext accueille Novagali Pharma sur son marché européen

Back

Paris, 22 July 2010 – Novagali Pharma, a pharmaceutical company that develops ophthalmic innovative products for treatment of all segments of the eye, today celebrated its listing on NYSE Euronext Paris.

Novagali Pharma (ticker symbol: NOVA) was admitted to NYSE Euronext by the listing of 6,359,882 existing shares making up its capital, 3,409,092 new shares resulting from the conversion of convertible bonds ('OCABSA') and the exercise of equity warrants ('BSAOCA'), 36,808 new shares granted in connection with the capital increase reserved to employees, and 6,468,750 new shares issued as part of a global offering, after the full exercise of the Over-Allotment Option. The total amount raised was €22 million. The admission and issue price of Novagali Pharma shares was set at €3.40 each. The company’s market capitalization on the day of admission amounted to €55.3 million.

NYSE Euronext accueille Novagali Pharma sur son marché européen

Press Release Footer

About Euronext 
Euronext is the leading European capital market infrastructure, covering the entire capital markets value chain, from listing, trading, clearing, settlement and custody, to solutions for issuers and investors. Euronext runs MTS, one of Europe’s leading electronic fixed income trading markets, and Nord Pool, the European power market. Euronext also provides clearing and settlement services through Euronext Clearing and its Euronext Securities CSDs in Denmark, Italy, Norway and Portugal.
As of September 2025, Euronext’s regulated exchanges in Belgium, France, Ireland, Italy, the Netherlands, Norway and Portugal host over 1,700 listed issuers with €6.5 trillion in market capitalisation, a strong blue-chip franchise and the largest global centre for debt and fund listings. With a diverse domestic and international client base, Euronext handles 25% of European lit equity trading. Its products include equities, FX, ETFs, bonds, derivatives, commodities and indices.
In November 2025, Euronext successfully acquired a majority stake in the Athens Stock Exchange (ATHEX), further expanding its footprint and strengthening its pan-European market infrastructure.

For the latest news and resources, please visit the Media Centre. 
Follow us on X (x.com/euronext) and LinkedIn (linkedin.com/company/euronext).

Disclaimer
This press release is for information purposes only and is not a recommendation to engage in investment activities. This press release is provided “as is” without representation or warranty of any kind. While all reasonable care has been taken to ensure the accuracy of the content, Euronext does not guarantee its accuracy or completeness. Euronext will not be held liable for any loss or damages of any nature ensuing from using, trusting or acting on information provided. No information set out or referred to in this publication may be regarded as creating any right or obligation. The creation of rights and obligations in respect of financial products that are traded on the exchanges operated by Euronext’s subsidiaries shall depend solely on the applicable rules of the market operator. All proprietary rights and interest in or connected with this publication shall vest in Euronext.

This press release speaks only as of this date. Euronext refers to Euronext N.V. and its affiliates. Information regarding trademarks and intellectual property rights of Euronext is located at www.euronext.com/terms-use.

© 2025, Euronext N.V. - All rights reserved.